Ophidion’s CNS Carrier Technology (OCCT) Derived Programs
Ophidion is addressing the problem of drug delivery into the CNS with an innovative and patented blood-brain-barrier traversing technology with proven preclinical proof-of-concept in animal models of Huntington’s and cognition. Multiple programs could potentially enter into the clinic in the next year to two years, addressing significant unmet needs in rare diseases as well as large markets.
These include Huntington’s disease (HD), diseases of cognitive impairment (e.g. Alzheimer’s disease, Parkinson’s disease), and Parkinson’s disease, Alzheimer’s disease, Frontotemporal Dementia, ALS, and Glioblastoma Multiforme.
